Arca
Skip to content
Tools
Tools

Polycythemia vera (PV)

Drug research and approvals for polycythemia vera (PV): what is recruiting, what Health Canada authorized, FDA orphan designations and EU medicines. See every condition.

As of Nov 21, 2026, 19 studies of polycythemia vera (PV) are recruiting on ClinicalTrials.gov, Health Canada has authorized 21 drug trials for it since 2013, FDA has 9 approved and 12 open orphan designations naming it, and the EU has 1 authorised medicine for it.

  • Recruiting worldwide: 19
  • Trials authorized in Canada: 21
  • FDA orphan approvals: 9
  • EU medicines: 1

Recruiting now

Newest posted first, of 19 recruiting on ClinicalTrials.gov ↗

Drug pipeline

Each drug at the furthest stage it has reached for this condition, from ChEMBL's drug indications

Approved 4

Phase 3 8

Phase 2 12 of 18

Phase 1 or earlier 9

How its trials ended

228 ClinicalTrials.gov studies of the condition, classified by TrialPanorama, partly automatically, so some labels are wrong

Of the 72 whose ending is known, 44% met their primary endpoint, 8% missed it and 47% stopped early.

  • Ongoing7533%
  • Completed, result not reported7131%
  • Met its primary endpoint3214%
  • Stopped: other or unclear198%
  • Status unknown104%
  • Missed its primary endpoint63%
  • Stopped: enrollment or feasibility52%
  • Stopped: sponsor or business decision52%
  • Stopped: lack of efficacy42%
  • Stopped: safety1<1%

Trials authorized in Canada

The 10 newest of 21; search them all in Canada trials
Sep 17, 2026A phase 2/3, randomized, open-label, active-comparator-controlled, parallel-group multicenter study to evaluate the safety and efficacy of bomedemstat…Bomedemstat (MK-3543)Merck & Co. (MSD)Pending
Apr 15, 2026A phase 3 randomized, double-blind, placebo-controlled global study of sapablursen in polycythemia veraSapablursen (ONO-0530, isis 702843)Ono PharmaceuticalPending
Jun 27, 2024An open label, multi-center, phase IV rollover protocol for patients who have completed a prior global novartis or incyte sponsored ruxolitinib (INC424) study…Ruxolitinib (INC424)Novartis PharmaceuticalsOngoing
Jan 12, 2024Randomized, open-label, multicenter phase 3 study to assess the efficacy and safety of givinostat versus hydroxyurea in JAK2V617F-positive high-risk…Givinostat (ITF2357) / HydroxyureaItalfarmacoClosed
Feb 2, 2023A phase IIIb, single-arm, multicenter study to access efficacy, safety, and tolerability of ropeginterferon ALFA-2B-njft (P1101) in adult patients with…Ropeginterferon ALFA-2B-NJFT (P1101)PharmaEssentiaOngoing
Apr 20, 2022A phase 3 study of the hepcidin mimetic rusfertide (PTG-300; TAK-121) in patients with polycythemia veraRusfertide (PTG-300, TAK-121)Takeda Pharmaceuticals USAOngoing
Jan 12, 2022A phase 2a, randomized, open-label study to evaluate the efficacy, safety, tolerability, pharmacokinetics, and pharmacodynamics of isis 702843 administered to…Sapablursen (isis 702843)Ionis PharmaceuticalsClosed
Nov 29, 2019A randomized, controlled phase 3 study of pacritinib versus physician's choice in patients with primary myelofibrosis, post polycythemia vera myelofibrosis, or…Pacritinib (SB1518) / Ruxolitinib / Hydroxyurea / DanazolSobiOngoing
Nov 13, 2019A randomized, double-blind, phase 3 study to evaluate the activity of momelotinib (MMB) versus danazol (DAN) in symptomatic, anemic subjects with primary…Momelotinib (MMB) / DanazolSierra OncologyOngoing
Jul 27, 2018A two-part, randomized, open-label, multicenter, phase 2a/2b study of the efficacy, safety, pharmacokinetics, and pharmacodynamics of KRT-232 compared to…KRT-232 / RuxolitinibKartos Therapeutics IncClosed

FDA orphan designations

Approved first, then open designations, newest first; 15 of 21
Aug 28, 2026MimryloTreatment of erythrocytosis in adults with polycythemia vera (PV)Takeda Development Center Americas, Inc. (a direct, wholly owned subsidiary of Takeda Pharmaceuticals U.S.A., Inc.)Approved
May 1, 2026Jakafi XRTreatment of polycythemia vera (PV) in adults who have had an inadequate response to or are intolerant of hydroxyureaIncyte CorporationApproved
May 1, 2026Jakafi XRTreatment of intermediate or high-risk myelofibrosis (MF), including primary MF, post-polycythemia vera MF, and post-essential…Incyte CorporationApproved
Sep 15, 2023OjjaaraTreatment of intermediate or high-risk myelofibrosis (MF), including primary MF or secondary MF [post-polycythemia vera (PV) and…GlaxoSmithKlineApproved
Feb 28, 2022VonjoTreatment of adults with intermediate or high-risk primary or secondary (post-polycythemia vera or post-essential thrombocythemia)…Sobi, Inc.Approved
Nov 12, 2021BesremiTreatment of adults with polycythemia veraPharmaEssentiaApproved
Aug 16, 2019InrebicINREBIC® is indicated for the treatment of adult patients with intermediate-2 or high-risk primary or secondary (post-polycythemia vera or…Impact Biomedicines, Inc. a wholly-owned subsidiary of Celgene CorporationApproved
Dec 4, 2014JakafiTreatment of patients with polycythemia vera who have had an inadequate response to or are intolerant of hydroxyurea.Incyte CorporationApproved
Nov 16, 2011JakafiTreatment of patients with intermediate or high-risk myelofibrosis, including primary myelofibrosis, post-polycythemia vera myelofibrosis…Incyte CorporationApproved
Jan 22, 2026Recombinant fully human IgG1 monoclonal antibodyTreatment of polycythemia veramAbTree Biologics AGDesignated
Aug 26, 2025Synthetic 19-mer peptide nucleic acid oligomer consisting…Treatment of polycythemia veraVanda Pharmaceuticals Inc.Designated
Dec 19, 2024Synthetic 2-O-methoxyethyl phosphorothioate…Treatment of polycythemia veraVanda Pharmaceuticals IncDesignated
Aug 5, 2024SapablursenTreatment of polycythemia vera (PV)Deciphera Pharmaceuticals, LLCDesignated
Feb 8, 2024Recombinant humanized monoclonal antibody targeting…Treatment of Polycythemia VeraDisc Medicine, Inc.Designated
Feb 24, 2022Synthetic double-stranded siRNA oligonucleotide directed…Treatment of Polycythemia Vera (PV)Silence Therapeutics plcDesignated

Medicines authorised in the EU

Newest first
AuthorisedMedicineHolderEPAR
Feb 15, 2019BesremiRopeginterferon alfa-2bAOP Orphan Pharmaceuticals GmbHEMA ↗

Condition names come from Health Canada's trial database. Orphan designations and EU medicines are matched when their indication names the condition as whole words, so a broader or differently worded indication can be missed. Recruiting counts are live from ClinicalTrials.gov's own condition search, refreshed daily. ClinicalTrials.gov, Health Canada Clinical Trials Database, FDA orphan designations, EMA

Esc

Type a name: a tool, a company, a drug or brand, a condition, a gene or a state. Identifiers like K231234, NCT05012345 or NDA 215866 open their record.

Logos are each company's own site icon, matched by name through Wikidata, or logos provided by Logo.dev.Company names and logos identify the companies in public FDA and registry records and do not imply endorsement.